The Association Between Prolactin Levels and Cognitive Function in Female Patients With Severe Mental Disorders
Article information
, Shun Yao1,2,*, Zhiying Yang1,2, Yuan Shi1,2, Xiaoqing Zhang1,2, Lijun Wang1,2, Donghong Cui,1,2,3
Abstract
Objective
Cognition impairments are considered as a fundamental characteristic of severe mental disorders (SMD). Recent studies suggest that hyperprolactinemia may exert a detrimental influence on cognitive performance in patients with SMD. The objective of this study was to investigate the correlation between serum prolactin levels and cognitive function in female individuals diagnosed with SMD.
Methods
We conducted a study on 294 patients with SMD and 195 healthy controls, aged between 14 to 55 years old. Cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), while prolactin levels were measured in serum. Descriptive analysis and comparative analysis were performed to compare cognitive function and prolactin levels between groups, and linear regression models were used to explore the relationship between prolactin and cognitive function.
Results
Compared to the healthy control, individuals with SMD exhibited significantly higher levels of prolactin, while scoring lower on RBANS total and every index scores. Furthermore, a negative association between prolactin levels and cognitive function (RBANS total index score, attention, and delayed memory) was observed in SMD patients. Importantly, this inverse correlation between prolactin and cognition function (RBANS total index score, total scale score, and attention) persisted in patients who were not taking medications that could potentially influence serum prolactin levels.
Conclusion
Our study reveals a significant correlation between elevated prolactin levels and cognitive impairment in female patients with SMD, underscoring the importance of monitoring prolactin levels in order to prevent cognitive deterioration among female SMD patients.
INTRODUCTION
Severe mental disorders (SMD) is a group of conditions that include schizophrenia (SZ), bipolar disorder (BD), and other psychotic disorders [1]. SZ and BD exhibit genetic overlap in their pathogenesis [2] and share certain symptoms [3]. Neurocognitive impairment has been recognized as one of the important common symptoms, not only been a core symptom of SZ [4], but also persistently demonstrated during remission in BD [5]. These cognitive deficits significantly contribute to functional disability in both SZ and BD [6]. Overall, cognitive impairments are considered as core feature of SMD and have shown predictive value for clinical and functional outcomes [7].
Current research on biomarkers of cognitive impairment has revealed an association between prolactin (PRL) and cognitive performance. A study conducted in young healthy pregnant women showed a negative linear association between PRL levels and executive function scores, suggesting that higher PRL levels have a detrimental effect on executive function abilities [8]. Furthermore, another study indicated elevated PRL levels in patients with Alzheimer’s disease, particularly in those with severe dementia [9]. In patients with prolactinomas, hyperprolactinemia may induce cognitive toxicity by affecting the prefrontal cortex of the brain [10].
However, there is a lack of research on the relationship between PRL levels and cognitive function in patients with SMD. A study conducted on individuals with early psychosis suggests that increased PRL levels may have negative effects on cognitive function. PRL was negatively associated with speed of processing (β=-0.283) after adjusting for psychopharmacological treatments [11]. They later found out that in men, PRL was associated with an impairment in most cognitive domains, whereas in women, only a component for processing speed (Brief Assessment of Cognition in Schizophrenia–Symbol Coding) was negatively affected [12]. These studies revealed that there was sex different in the association between PRL and cognitive performance. Given that serum PRL values follow a lognormal distribution in healthy young women [13] and were comparatively stable in males [14], we selected females aged 14–55 years (post-menarche [15] and pre-menopause [16]) to investigate the relationship between PRL levels and cognitive function.
The objective of our study was to investigate the impact of PRL levels on cognitive function in Chinese women with SMD. Identifying biomarkers that can predict cognitive impairment in female SMD patients has the potential to enhance diagnosis and therapeutic strategies in clinical practice.
METHODS
Subjects
Data were drawn from the Shanghai Mental Health Center (SMHC) Key Laboratory Precision Medicine Project, which aimed to study SMD through the integration of genetic, imaging, and clinical features. Patients were recruited from multiple institutions including SMHC, Shanghai Civil Affairs First Mental Health Center, Cixi Mental Health Center, Quzhou Third People’s Hospital, and Huzhou Third People’s Hospital between January 2017 and January 2020. All patients who met the diagnosis of SZ and BD were included, and the diagnosis was made by experienced psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Healthy controls (HC) were recruited from the local community through advertisements, and screened to exclude individuals with a personal or family history of psychiatric disorders. Both patients and HC were interviewed by trained raters using the Mini-International Neuropsychiatric Interview to confirm the clinical diagnosis or to screen whether the controls have any major Axis I disorder diagnosis.
Exclusion criteria were cerebral vascular disease, central nervous system diseases, severe physical diseases, substance abuse/dependence, pregnancy, or lactation.
Of all participants screened, 491 met the predefined inclusion criteria. Subsequently, samples were categorized into two distinct populations: 1) SMD (n=195), including 83 SZ patients and 112 BD patients (the proportions of type 1 and type 2 bipolar patients as 73 and 39, respectively), 2) HC (n=294).
The protocol was reviewed and approved by the ethics committee at SMHC (IRB No. 2019-35R). Written informed consent was obtained from all subjects before the study.
Cognitive assessment
The cognitive function of participants was assessed at each center using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS, Form A) [17]. This battery comprises 12 subtests that are utilized to calculate five age-adjusted index scores and a total index score. A total scale score is calculated in accordance with the instructions provided in the stimulus booklet appendix. The test indices include immediate memory (comprised of list learning and story memory tasks), visuospatial/constructional (comprised of figure copy and line orientation tasks), language (comprised of picture naming and semantic fluency tasks), attention (comprised of digit span and coding tasks), and delayed memory (comprised of list recall, story recall, figure recall, and list recognition tasks). The inter-rater correlation coefficient for assessments was greater than 0.8.
PRL measurements
PRL measurements were conducted using immunoassays with standardized protocols at each center. The same standard samples were tested and the results obtained from multiple centers were standardized in order to minimize systematic errors. The participants were instructed to refrain from experiencing stress, engaging in physical activity, stimulating their breasts, and smoking within the 12 hours preceding blood sampling. Blood sample were collected between 8 and 10 am after overnight fast and 30 min of rest by technicians who were blind to the diagnostic status of subjects.
Other variables
Clinical variables related to psychosis (including sex, age, education level, use of antipsychotics, and other medications) were collected using the self-designed questionnaire. All data were recorded by the same researcher.
Psychopharmacological treatments
Psychopharmacological treatments were documented during the neuropsychological assessment. Several antipsychotics, including risperidone, paliperidone, amisulpride, aripiprazole, and benzamide have been reported in existing studies to potentially impact PRL levels in blood [18].
Among all individuals diagnosed with SMD, 38 were prescribed these specific antipsychotic medications.
Statistical analysis
The Shapiro–Wilk test was utilized to assess normality. Sociodemographic differences were analyzed using Student’s t-tests or the Mann–Whitney test, while PRL levels and RBANS scores were compared between controls and SMD patients using the Mann–Whitney test. Linear regression models were performed to explore the relationship between PRL and cognitive function, with original RBANS scores and log-transformed PRL values. The residual plots were utilized to assess whether the residuals conform to the assumptions of normality and homoscedasticity. All analyses were adjusted for covariates including age and education levels.
All data were analyzed using the R environment for statistical computing (R studio, 4.2.2; R Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org). Statistical significance was determined at a threshold of p<0.05 (two-tailed).
RESULTS
Univariate analysis
Clinical characteristics, RBANS total and index scores of the sample by groups (195 with SMD and 294 HC) are presented in Table 1. Additional information about the patients are provided in Supplementary Table 1.
Clinical variables and RBANS scores by diagnostic groups
There were no significant age differences observed between the HC and SMD groups. However, it is noteworthy that PRL levels were significantly higher in SMD subjects compared to HC subjects (479.4 mIU/L vs. 323.8 mIU/L, p<0.001). As expected, SMD patients scored lower on RBANS total and every index scores. A notable discrepancy was observed in both RBANS total index scores (435.0 vs. 493.0, p<0.001) and total scale score (82.0 vs. 97.0, p<0.001) among the groups. Large differences were also evident in immediate memory, visuospatial, language, attention and delayed memory scores between individuals with SMD and controls. These findings suggest that SMD patients exhibited poorer performance in cognitive tasks.
Correlation of PRL and cognitive tasks
Linear regression analyses investigating the association between PRL and RBANS total and index scores are presented in Table 2. Among individuals with SMD, a negative correlation was found between PRL levels and RBANS total index score (β=-23.21, p=0.0231). Additionally, elevated PRL levels were associated with poorer attention (β=-8.12, p=0.0057) and delayed memory performance (β=-6.01, p=0.0386) among SMD patients. However, no significant associations were observed between PRL levels and RBANS scores in HC, including total score, immediate memory, visuospatial ability, language skills or delayed memory. Attention was positively correlated with PRL levels (β=9.55, p=0.0056). These findings provide valuable insights into the relationships between PRL levels and cognitive performance across different population.
Results of regression analysis exploring the relationship between prolactin levels and RBANS scores among SMD and HC
Sensitivity analysis
Considering that individuals with SMD included in this study had a documented history of stable medication use, we investigated the relationship between PRL levels and cognitive function in patients who were not taking medications that may affect serum PRL level. Out of the 195 SMD patients with reliable medication records prior to PRL measurements, 157 were naïve for the intake of those antipsychotic medication (as described in the methods).
Linear regression analyses revealed a sustained association between PRL and cognitive function in SMD patients. Specifically, higher serum PRL levels were found to be negatively correlated with RBANS score (RBANS total scale score: β=-6.01, p=0.0266; RBANS total index score: β=-29.67, p=0.0126; attention: β=-10.02, p=0.0035), indicating that higher PRL levels were related with worse cognitive performance (Table 3). This finding supports the notion that the association between PRL levels and cognitive function in patients with SMD may be independent of medication presence. We further conducted an analysis based on diagnostic groups (SZ vs. BD), as depicted in Figure 1. In both SZ and BD groups, the total scale score of RBANS decreased with the increase of PRL levels, which was consistent with the results obtained in SMD. The above findings provide additional validation for our observation of a negative correlation between PRL levels and cognition function in SMD patients.
Results of regression analysis exploring the relationship between prolactin levels and RBANS score in SMD who were not on medications that effect prolactin levels in body
Scatter plot of the relationship between prolactin levels and RBANS total scale scores between diagnostic groups (bipolar disorder vs. schizophrenia). Prolactin values were log transformed. RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.
DISCUSSION
Our study suggests that increased PRL levels are associated with impaired cognition function, independent of the use of antipsychotic drugs in patients with SMD. These patients exhibit poorer cognitive function and higher PRL levels compared to the general population. After adjusting for age and education, we observed a significant negative correlation between PRL levels and cognitive function. Importantly, this correlation remained robust even after excluding patients who were taking medications known to potentially influence PRL levels. To the best of our knowledge, this is the first study to highlight the significance of PRL as a crucial factor contributing to cognitive impairment in Chinese females with SMD.
In terms of cognitive function, our results are consistent with previous studies suggesting that there is a gradient of cognitive impairment from BD to SZ, which may represent a symptom dimension that crosses traditional diagnostic boundaries [19]. These deficits, considered as fundamental characteristics of SMD, are believed to precede the onset of psychiatric illnesses and have predictive value for functional outcomes [20]. Furthermore, our study revealed inferior performance across all cognitive domains in patients with SMD.
Traditionally, hyperprolactinemia in patients with mental disorder has been regarded as an adverse effect of antipsychotic drugs. However, elevated PRL levels or hyperprolactinemia has also been observed in patients with first-episode psychosis without antipsychotic medication or those at high risk for psychosis, particularly among women [21,22]. In our study, PRL elevation also found in SMD. This finding aligns with the hypothesis of hyperprolactinemia in SZ suggesting that stress can trigger the outbreak of psychosis through a feedback mechanism involving enhanced PRL leading to increase dopamine release [21].
In patients who were not taking medications known to affect PRL levels in body, a significant association was observed between higher PRL levels and poorer cognitive function. These results are consistent with previous studies conducted in early psychosis [11]. The propensity of antipsychotics to induce hyperprolactinemia varies due to differences in D2 receptor binding activity and duration within brain [23]. Additionally, multivariate analyses indicate an independent effect of PRL on cognitive function, as all analyses were adjusted for age and education level.
The relationship between PRL and SMD may be explained by hypothalamic-pituitary-gonadal axis hypothesis. According to this hypothesis, stress causes an increase in PRL, which enhances dopamine release (i.e., prolactin inhibiting factor) in a feedback mechanism. Increased dopamine triggers psychotic symptoms in people who are prone to psychosis [24]. Although the mechanisms linking higher levels of PRL to poorer cognitive performance are unknown, recent research showed that patients with prolactinomas demonstrated a decrease in gray matter volumes (GMV) in the left hippocampus, left orbitofrontal cortex, right middle frontal cortex (MFC), and right inferior frontal cortex (IFC). In addition, patients performed worse than controls on tests for verbal memory and executive function, and this was significantly related to the GMV of the left hippocampus and right MFC, respectively. Moreover, serum PRL levels were negatively related with the GMV of the left hippocampus and right IFC, suggesting a potential “neurotoxic” effect of PRL to brain [25]. The reduction in PRL levels via treatment was followed by improvements in processing speed, working memory, visual learning and reasoning and problem-solving in patients with prolactinomas [26]. Although no proof-of-concept trial was conducted in SMD patients, it is plausible to speculate that the negative association of PRL with cognitive function might rely on the direct effect of PRL on brain, as PRL plays important roles as a neuropeptide and regulates neurogenesis in both the subventricular zone and the dentate gyrus of the hippocampal formation [27], suggesting a potential role of PRL in the brain in aspects other than reproductive function, including cognitive abilities. Further studies are needed to better understand the relation between PRL, SMD, and cognitive performance.
The main limitation of our study is the cross-sectional design that does not allow us to infer causality. Future prospective studies are necessary to ascertain whether persistent hyperprolactinemia is a risk factor for impaired cognition in people with SMD by repeatedly assessing PRL levels and cognitive function over time. The majority of the patients in our study were taking antipsychotics and had a long course of disease, which may affect PRL level and cognitive performance. Thus, our finding needs to be validated in patients with first episode of SMD. Moreover, our subjects were all Chinese women. This study is needed to be confirmed in other ethnicities and with a larger sample size in the future.
In conclusion, our study suggests that increased PRL levels are negatively associated with cognitive function in Chinese female patients with SMD. Our study suggests that PRL may be considered as a potential biomarker for cognitive impairment in individuals with SMD. This finding highlights the significance of monitoring PRL levels in female SMD patients to prevent cognitive deterioration.
Supplementary Materials
The Supplement is available with this article at https://doi.org/10.30773/pi.2024.0008.
Clinical information of SZ and BD patients
Notes
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Conflicts of Interest
The authors have no potential conflicts of interest to disclose.
Author Contributions
Conceptualization: Yichong Xu, Shun Yao, Zhiying Yang, Donghong Cui. Data curation: Yuan Shi, Xiaoqing Zhang, Lijun Wang. Formal analysis: Yichong Xu, Shun Yao. Funding acquisition: Donghong Cui, Shun Yao. Investigation: Yuan Shi. Methodology: Yichong Xu, Shun Yao, Zhiying Yang. Project administration: Yuan Shi. Resources: Donghong Cui. Software: Yichong Xu, Shun Yao. Supervision: Shun Yao, Donghong Cui. Validation: Shun Yao, Donghong Cui. Visualization: Yichong Xu, Shun Yao. Writing—original draft: Yichong Xu, Shun Yao. Writing—review & editing: Shun Yao, Donghong Cui.
Funding Statement
This research was supported by grants from the National Key R&D Program of China (No: 2017YFC0909200) and the National Natural Science Foundation of China (No: 82271544) for Donghong Cui; the grant from Shanghai Mental Health Center (2021-QH-02) for Shun Yao.
Acknowledgements
We are grateful to Donghong Cui, Shun Yao for designing the study and proofreading the manuscript.